Desmond Pj Barton
Research Subjects
Research Interests
Desmond Pj Barton has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Desiree F Kolomainen
Southend NHS Foundation Trust Essex and East Suffolk Cancer Group Essex UK
2 shared publications- M. A. E. Nobbenhuis
Department of Gynaecological Oncology, The Royal Marsden Hospital, London SW3 6JJ, UK
2 shared publications - Thomas Ind
Department of Gynaecological Oncology, Royal Marsden Hospital, 203 Fulham Rd., London SW3 6JJ, United Kingdom
2 shared publications - Alexandra Lawrence
Department of Gynaecological Oncology, Royal London Hospital, Barts Health NHS Trust, London E1 1FR, UK
1 shared publication - Ann Ward
Section of Cancer Genetics, The Institute of Cancer Research & The Royal Marsden Foundation Trust, Cotswold Road and Fulham Road, SW3 6JJ, London, UK
1 shared publication - Arjun Jeyarajah
Department of Gynaecological Oncology, Royal London Hospital, Barts Health NHS Trust, London E1 1FR, UK
1 shared publication
Latest Publications
- Open Access
- 20 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (22) , 3484
Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis
For women achieving clinical remission after the completion of initial treatment for epithelial ovarian cancer, 80% with advanced-stage disease will develop recurrence. However, the standard treatment of women with recurrent platinum-sensitive diseases remains poorly defined. Secondary (SCS), tertiary (TCS) or quaternary (QCS) cytoreduction surgery for recurrence has been suggested to be associated with increased overall survival (OS). We searched five databases for studies reporting death rate, OS, cytoreduction rates, post-operative morbidity/mortality and diagnostic models predicting complete cytoreduction in a platinum-sensitive disease recurrence setting. Death rates calculated from raw data were pooled based on a random-effects model. Meta-regression/linear regression was performed to explore the role of complete or optimal cytoreduction as a moderator. Pooled death rates were 45%, 51%, 66% for SCS, TCS and QCS, respectively. Median OS for optimal cytoreduction ranged from 16–91, 24–99 and 39–135 months for SCS, TCS and QCS, respectively. Every 10% increase in complete cytoreduction rates at SCS corresponds to a 7% increase in median OS. Complete cytoreduction rates ranged from 9–100%, 35–90% and 33–100% for SCS, TCS and QCS, respectively. Major post-operative thirty-day morbidity was reported to range from 0–47%, 13–33% and 15–29% for SCS, TCS and QCS, respectively. Thirty-day post-operative mortality was 0–6%, 0–3% and 0–2% for SCS, TCS and QCS, respectively. There were two externally validated diagnostic models predicting complete cytoreduction at SCS, but none for TCS and QCS. In conclusion, our data confirm that maximal effort higher order cytoreductive surgery resulting in complete cytoreduction can improve survival.
- 20 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (22) , 3484
Open AccessPrognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis
For women achieving clinical remission after the completion of initial treatment for epithelial ovarian cancer, 80% with advanced-stage disease will develop recurrence. However, the standard treatment of women with recurrent platinum-sensitive diseases remains poorly defined. Secondary (SCS), tertiary (TCS) or quaternary (QCS) cytoreduction surgery for recurrence has been suggested to be associated with increased overall survival (OS). We searched five databases for studies reporting death rate, OS, cytoreduction rates, post-operative morbidity/mortality and diagnostic models predicting complete cytoreduction in a platinum-sensitive disease recurrence setting. Death rates calculated from raw data were pooled based on a random-effects model. Meta-regression/linear regression was performed to explore the role of complete or optimal cytoreduction as a moderator. Pooled death rates were 45%, 51%, 66% for SCS, TCS and QCS, respectively. Median OS for optimal cytoreduction ranged from 16–91, 24–99 and 39–135 months for SCS, TCS and QCS, respectively. Every 10% increase in complete cytoreduction rates at SCS corresponds to a 7% increase in median OS. Complete cytoreduction rates ranged from 9–100%, 35–90% and 33–100% for SCS, TCS and QCS, respectively. Major post-operative thirty-day morbidity was reported to range from 0–47%, 13–33% and 15–29% for SCS, TCS and QCS, respectively. Thirty-day post-operative mortality was 0–6%, 0–3% and 0–2% for SCS, TCS and QCS, respectively. There were two externally validated diagnostic models predicting complete cytoreduction at SCS, but none for TCS and QCS. In conclusion, our data confirm that maximal effort higher order cytoreductive surgery resulting in complete cytoreduction can improve survival.
- 17 April 2017
- Published by Wiley in The Obstetrician & Gynaecologist
- Vol. 19 (2) , 109-118
Pelvic exenteration for recurrent gynaecological cancer after radiotherapy
Key content: Exenterative procedures for recurrent gynaecological cancers are uncommon and present clinical challenges. A multidisciplinary approach is key to optimising patient outcome. Surgery is undertaken in almost all cases with curative intent, and rarely with palliative intent. Only complete histological clearance of disease (R0 resection) is associated with long‐term survival, but not in all cases. There is an absence of level 1 evidence and national guidelines. Learning objectives: Understand the factors that are important in case selection. Appreciate that case selection is individualised and surgery is associated with a high morbidity and mortality rates. Understand the two components of exenterative surgery: (1) complete resection of the cancer (R0) and (2) reconstruction/restoration of pelvic functions. Most exenterations are performed for recurrent disease involving the central pelvis. Recently, radical surgery has been undertaken with favourable outcomes for pelvic sidewall disease. Ethical issues: There is a paucity of data on quality‐of‐life assessment in patients undergoing exenterative surgery for recurrent gynaecological cancers. Prolonged survival may not translate into improved or acceptable quality of life. Following success from the centralisation of cancer services, consideration needs to be given to commissioning exenterative procedures in fewer centres in the UK.
- 17 April 2017
- Published by Wiley in The Obstetrician & Gynaecologist
- Vol. 19 (2) , 109-118
Pelvic exenteration for recurrent gynaecological cancer after radiotherapy
Key content: Exenterative procedures for recurrent gynaecological cancers are uncommon and present clinical challenges. A multidisciplinary approach is key to optimising patient outcome. Surgery is undertaken in almost all cases with curative intent, and rarely with palliative intent. Only complete histological clearance of disease (R0 resection) is associated with long‐term survival, but not in all cases. There is an absence of level 1 evidence and national guidelines. Learning objectives: Understand the factors that are important in case selection. Appreciate that case selection is individualised and surgery is associated with a high morbidity and mortality rates. Understand the two components of exenterative surgery: (1) complete resection of the cancer (R0) and (2) reconstruction/restoration of pelvic functions. Most exenterations are performed for recurrent disease involving the central pelvis. Recently, radical surgery has been undertaken with favourable outcomes for pelvic sidewall disease. Ethical issues: There is a paucity of data on quality‐of‐life assessment in patients undergoing exenterative surgery for recurrent gynaecological cancers. Prolonged survival may not translate into improved or acceptable quality of life. Following success from the centralisation of cancer services, consideration needs to be given to commissioning exenterative procedures in fewer centres in the UK.
- 24 January 2017
- Published by Wiley in The Obstetrician & Gynaecologist
- Vol. 19 (1) , 63-70
Surgical management of bowel obstruction in gynaecological cancer
- 24 January 2017
- Published by Wiley in The Obstetrician & Gynaecologist
- Vol. 19 (1) , 63-70
Surgical management of bowel obstruction in gynaecological cancer
- 1 November 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 131 (2) , 347-351
Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial ovarian cancer (PAEOC): A questionnaire survey
- 1 November 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 131 (2) , 347-351
Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial ovarian cancer (PAEOC): A questionnaire survey
- Open Access
- 19 January 2013
- Published by Springer Nature
Groin ultrasound and fine needle aspiration cytology in the conservative management of the groin nodes in primary squamous cell cancer of the vulva
- 19 January 2013
- Published by Springer Nature
Open AccessGroin ultrasound and fine needle aspiration cytology in the conservative management of the groin nodes in primary squamous cell cancer of the vulva
- Open Access
- 23 November 2011
- Published by Springer Nature in Hereditary Cancer in Clinical Practice
- Vol. 9 (1) , 11
Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests
We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer. 545 women with a positive family history of ovarian cancer referred to the Ovarian Screening Service at the Royal Marsden Hospital, London from January 2000- December 2008 were included. They were stratified into three risk-groups according to family history (high-, moderate- and low-risk) of developing ovarian cancer and offered annual serum CA 125 and transvaginal ultrasound screening. The high-risk group was offered genetic testing. The median age at entry was 44 years. The number of women in the high, moderate and low-risk groups was 397, 112, and 36, respectively. During 2266 women years of follow-up two ovarian cancer cases were found: one advanced stage at her fourth annual screening, and one early stage at prophylactic bilateral salpingo-oophorectomy (BSO). Prophylactic BSO was performed in 138 women (25.3%). Forty-three women had an abnormal CA125, resulting in 59 repeat tests. The re-call rate in the high, moderate and low-risk group was 14%, 3% and 6%. Equivocal transvaginal ultrasound results required 108 recalls in 71 women. The re-call rate in the high, moderate, and low-risk group was 25%, 6% and 17%. No early stage ovarian cancer was picked up at annual screening and a significant number of re-calls for repeat screening tests was identified.
- 23 November 2011
- Published by Springer Nature in Hereditary Cancer in Clinical Practice
- Vol. 9 (1) , 11
Open AccessScreening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests
We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer. 545 women with a positive family history of ovarian cancer referred to the Ovarian Screening Service at the Royal Marsden Hospital, London from January 2000- December 2008 were included. They were stratified into three risk-groups according to family history (high-, moderate- and low-risk) of developing ovarian cancer and offered annual serum CA 125 and transvaginal ultrasound screening. The high-risk group was offered genetic testing. The median age at entry was 44 years. The number of women in the high, moderate and low-risk groups was 397, 112, and 36, respectively. During 2266 women years of follow-up two ovarian cancer cases were found: one advanced stage at her fourth annual screening, and one early stage at prophylactic bilateral salpingo-oophorectomy (BSO). Prophylactic BSO was performed in 138 women (25.3%). Forty-three women had an abnormal CA125, resulting in 59 repeat tests. The re-call rate in the high, moderate and low-risk group was 14%, 3% and 6%. Equivocal transvaginal ultrasound results required 108 recalls in 71 women. The re-call rate in the high, moderate, and low-risk group was 25%, 6% and 17%. No early stage ovarian cancer was picked up at annual screening and a significant number of re-calls for repeat screening tests was identified.